Issuance and repurchase of class C shares for incentive program
The board of directors of Cinclus Pharma Holding AB (publ) has today resolved to issue a total of 1,000,000 new class C shares and to immediately thereafter repurchase such 1,000,000 issued class C shares, for the purpose of the outstanding long term incentive program Performance Share Program 2026/2029. Today’s resolution by the board of directors was passed based on the authorization granted by the annual general meeting held on 21 May 2026.
Nordic Issuing AB will subscribe for all issued class C shares at a subscription price of approximately SEK 0.019413 per share, equal to the quota value of the shares. All 1,000,000 issued class C shares will be repurchased by Cinclus Pharma Holding AB (publ) for the same price per share. Following the share issue, the share capital will increase by SEK 19,413.284916. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.
The purpose of the issue and repurchase is to ensure future delivery of shares to participants in, as well as to cover any costs for social contributions arising as a result of, Performance Share Program 2026/2029. The class C shares will be reclassified to ordinary shares before delivery to the participants in the program.
Cinclus Pharma Holding AB (publ) will, following the issuance and repurchase of the 1,000,000 class C shares, hold all class C shares in the company.
For additional information, please contact:
Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com
Henrik Vikström, IR
Phone: +46 70 952 80 06
e-mail: henrik.vikström@cincluspharma.com
About Cinclus Pharma
Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.